The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 2 study of elraglusib (9-ING-41), a glycogen synthase kinase-3b inhibitor, in combination with gemcitabine plus nab-paclitaxel (GnP) in patients with previously untreated advanced pancreatic ductal adenocarcinoma (PDAC).
 
Devalingam Mahalingam
Consulting or Advisory Role - Amgen; OncoOne; Qurient
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Eisai; Exelixis; Genentech
Research Funding - Merck KGaA; Oncolytics
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)
 
Steven Francis Powell
Consulting or Advisory Role - Bristol-Myers Squibb (Inst)
Speakers' Bureau - Alkermes (Inst)
Research Funding - Actuate Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Incyte (Inst); Merck Sharp & Dohme (Inst); Molecular Templates (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Sorrento Therapeutics (Inst); Vyriad (Inst)
 
Marisol Huerta Alvaro
No Relationships to Disclose
 
Vaibhav Sahai
Consulting or Advisory Role - AstraZeneca; Autem Medical; GlaxoSmithKline; Histosonics; Incyte; Ipsen; QED Therapeutics; Rafael Pharmaceuticals; SERVIER
Research Funding - Actuate Therapeutics (Inst); Agios (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Debiopharm Group (Inst); Exelixis (Inst); FibroGen (Inst); Incyte (Inst); Ipsen (Inst); MedImmune (Inst); Pancreatic Cancer Action Network (Inst); Rafael Pharmaceuticals (Inst); Relay Therapeutics (Inst); Syros Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - ASCO; Lynx Group
 
Andrew L. Coveler
Consulting or Advisory Role - Abbvie; Halozyme; Merrimack; Seagen
Research Funding - AbGenomics International (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Amgen (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Immunomedics (Inst); Lilly (Inst); MedImmune (Inst); Newlink Genetics (Inst); Nextrast (Inst); Novocure (Inst); Nucana (Inst); Onconova Therapeutics (Inst); Seagen (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); XBiotech (Inst)
Travel, Accommodations, Expenses - Abbvie; Halozyme; Nucana
 
Elizabeth J. Davis
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Aadi; Deciphera
Speakers' Bureau - Physicans' Education Resource
Research Funding - Actuate Therapeutics (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Incyte (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); TopAlliance BioSciences Inc (Inst)
 
Neeltje Steeghs
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Cogent Biosciences (Inst); Ellipses Pharma (Inst); Luzsana Biotechnology (Inst)
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); Ascendis Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Bristol-Myers Squibb (Inst); Cantargia AB (Inst); CellCentric (Inst); Cogent Biosciences (Inst); Crescendo Biologics (Inst); Cytovation (Inst); Deciphera (Inst); Dragonfly Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); InteRNA (Inst); Janssen (Inst); Kinnate Biopharma (Inst); Kling Biotherapeutics (Inst); Lilly (Inst); Luzsana Biotechnology (Inst); Merck KGaA (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Molecular Partners (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Mary Frances Mulcahy
No Relationships to Disclose
 
Alexander G Raufi
No Relationships to Disclose
 
Ludimila Cavalcante
Employment - Actuate Therapeutics
Stock and Other Ownership Interests - Actuate Therapeutics
Consulting or Advisory Role - Pliant
 
Andres Cervantes
Consulting or Advisory Role - Amgen (Inst); Foundation Medicine (Inst); Merck Serono (Inst); Roche (Inst); Transgene (Inst)
Research Funding - Actuate Therapeutics (Inst); Adaptimmune (Inst); Amcure (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Spain (Inst); Bayer (Inst); BeiGene (Inst); BMSi (Inst); FibroGen (Inst); Genentech (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Natera (Inst); Novartis (Inst); SERVIER (Inst); Sierra Oncology (Inst); Takeda (Inst)
Other Relationship - Annals of Oncology; Cancer Treatment Reviews; ESMO Open
 
Jordan Berlin
Consulting or Advisory Role - Bayer Health; Bexion; BioSapien; insmed; ipsen; Merck KGaA; Merus; Mirati Therapeutics; Oxford BioTherapeutics
Research Funding - 23andMe (Inst); Abbvie (Inst); Astellas Pharma (Inst); Atreca (Inst); Bayer (Inst); Bristol-Myers Squibb/Celgene (Inst); Day One Biopharmaceuticals (Inst); Dragonfly Therapeutics (Inst); EMD Serono (Inst); hibercell (Inst); I-MAB (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); pfizer (Inst); PsiOxus Therapeutics (Inst); Sumitomo Dainippon Pharma Oncology (Inst); Totus Medicines (Inst); Tyra Biosciences (Inst)
Other Relationship - AstraZeneca; Boehringer Ingelheim; novocure
 
Janna Afanasjeva
Honoraria - Actuate Therapeutics
Consulting or Advisory Role - Actuate Therapeutics
 
William Mikrut
Honoraria - Actuate Therapeutics
Consulting or Advisory Role - Actuate Therapeutics
 
Sheri Lynn Smith
Employment - Courante Oncology
Stock and Other Ownership Interests - 3M
Consulting or Advisory Role - Actuate Therapeutics (Inst); Asymmetric Therapeutics; Celcuity (Inst); Hibercell; Humanetics (Inst); Medtronic (Inst); Neuspera; Panbela Therapeutics (Inst)
 
Francis J. Giles
Consulting or Advisory Role - Actuate Therapeutics
 
Benedito A. Carneiro
Consulting or Advisory Role - Eisai; Seagen; Tempus
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Dragonfly Therapeutics (Inst); MiNK Therapeutics (Inst); Pfizer (Inst); Repare Therapeutics (Inst)